Clinical Trials
471
55 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
11
2.3%
Completed
172
36.5%
Enrolling By Invitation
12
2.5%
Not yet recruiting
32
6.8%
Recruiting
78
16.6%
Terminated
10
2.1%
Unknown
151
32.1%
Withdrawn
5
1.1%
No approval data available
- China Medical University Hospital and Ever Supreme Bio Technology have developed αDAT-EV, the world's first actively navigated brain-targeting exosome platform capable of transporting therapeutic agents across the blood-brain barrier. - The platform uses genetic engineering to modify exosome surfaces with antibody fragments that recognize dopamine transporter (DAT), enabling precise targeting of dopaminergic neurons affected in Parkinson's disease. - Preclinical studies demonstrate the platform successfully delivers curcumin to key brain regions, activates cellular repair mechanisms, and improves motor function in Parkinson's disease animal models. - The versatile platform shows potential for delivering various therapeutic agents including small molecules, mRNA, and proteins for multiple CNS disorders including Alzheimer's disease and stroke.
- SOB100, developed by China Medical University Hospital and Shine-On Biomedical, represents the world's first exosome-based drug delivery platform specifically targeting HLA-G for cancer treatment. - The FDA approved Phase I clinical trials for SOB100 on March 8, 2025, following promising preclinical results in aggressive cancers including breast cancer and glioblastoma. - The platform uses nanobody technology to deliver therapeutic agents across the blood-brain barrier while minimizing systemic toxicity compared to conventional chemotherapy. - Shine-On Biomedical has been recognized as one of the top 10 global developers of exosome-based therapies and has established international partnerships for commercial expansion.
- Avance Clinical, a global Contract Research Organization, has signed Memorandums of Understanding with four premier Taiwanese medical institutions, strengthening its GlobalReady model for biotech companies. - The partnerships with Taichung Veterans General Hospital, Taipei Medical University, China Medical University Hospital, and Kaohsiung Medical University Chung-Ho Memorial Hospital provide US biotechs access to Taiwan's advanced healthcare infrastructure and diverse patient populations. - This strategic expansion leverages Taiwan's regulatory efficiency and clinical expertise, particularly in areas like CAR-T cell immunotherapy, to accelerate innovative treatment development for patients worldwide.
- St Vincent's Hospital Melbourne has established a partnership with China's Sichuan Provincial People's Hospital to conduct joint multi-center clinical trials focusing on drugs, medical devices, and digital solutions. - China Medical University Hospital (CMUH) signed an MOU with AbbVie in December 2024, combining CMUH's clinical research capabilities with AbbVie's global R&D resources to enhance trial efficiency in the Asia Pacific region. - Both partnerships include knowledge exchange programs, with St Vincent's focusing on research nurse training while CMUH-AbbVie collaboration aims to optimize trial processes and improve patient recruitment.
